BioCryst Pharmaceuticals Files 8-K on Financials
Ticker: BCRX · Form: 8-K · Filed: Aug 4, 2025 · CIK: 882796
Sentiment: neutral
Topics: financial-reporting, operations
Related Tickers: BCRX
TL;DR
BioCryst dropped an 8-K on August 4th detailing financial results and operations.
AI Summary
BioCryst Pharmaceuticals, Inc. filed an 8-K on August 4, 2025, reporting on its results of operations and financial condition. The filing also includes information related to Regulation FD disclosure and financial statements and exhibits. The company is incorporated in Delaware and headquartered in Durham, North Carolina.
Why It Matters
This 8-K filing provides crucial updates on BioCryst Pharmaceuticals' financial performance and operational status, which can influence investor decisions.
Risk Assessment
Risk Level: low — This is a routine financial filing (8-K) that doesn't appear to contain any immediate negative or positive material news.
Key Players & Entities
- BioCryst Pharmaceuticals, Inc. (company) — Registrant
- August 4, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- Durham, North Carolina (location) — Principal Executive Offices
- 000-23186 (filing_id) — SEC File Number
FAQ
What specific financial results are being reported in this 8-K?
The filing indicates it pertains to 'Results of Operations and Financial Condition' but does not provide specific figures within the provided text.
What is the purpose of the Regulation FD Disclosure mentioned?
The Regulation FD Disclosure item indicates the filing includes information intended to comply with the Fair Disclosure Regulation, ensuring broad public dissemination of material information.
What types of financial statements and exhibits are included?
The filing lists 'Financial Statements and Exhibits' as an item, but the specific contents are not detailed in the provided text.
When was BioCryst Pharmaceuticals, Inc. incorporated?
BioCryst Pharmaceuticals, Inc. was incorporated in Delaware.
What is the principal business address of BioCryst Pharmaceuticals, Inc.?
The principal executive offices are located at 4505 Emperor Blvd., Suite 200, Durham, North Carolina 27703.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on August 4, 2025 regarding BIOCRYST PHARMACEUTICALS INC (BCRX).